BM, BCh, MA
Jacquetta Blacker, MD, MA, joined UMN following several years working for the Mayo Clinic and Mayo Clinic Health System. A native of the United Kingdom, she earned her BMBCh (the equivalent of an MD) in medicine and surgery, and her Master of Arts and undergraduate degree in Physiological Sciences at Oxford University. Dr. Blacker completed her general psychiatric residency and a child and adolescent psychiatry (CAP) Fellowship at the Mayo Clinic in Rochester, and she is board certified in both adult and child and adolescent psychiatry.
Being at the University enables Dr Blacker to teach and she is currently the program director of UMN’s CAP fellowship. She also works with the neuromodulation team and consults with adults and children at the UMMC campus. She has a long-standing enjoyment of public speaking, and lectures and holds teaching seminars on a huge range of topics. She enjoys collaborating with colleagues on research projects, especially those related to bipolar and anxiety disorders, and her passion is medical history.
(for academic support only)
In the Media
- 2022: Featured in this article titled, "Child and Adolescent Psychiatry Fellowship making meaningful changes to improve the fellows’ experience".
Dr. Blacker's research interests include mood and anxiety disorders in medical-surgical populations, and suicide among medical professionals. Being part of a much larger institution that has many disciplines – and the opportunities that creates for doing cross-disciplinary work – is exciting to Blacker. "A lot of what I do is historical, looking at trends over time, how concepts have changed, how treatment has changed," she said. "Having access to specialists in history and statistics will really help move my research along." Dr. Blacker was co-investigator for three research grants, one looking at developing biomarkers that would lead to individualized treatments in bipolar patients with and without comorbid addiction; another used EEG to identify potential markers of suicidal behaviors in children between age 13-18; another examined biochemical and genetic differences in mood disorders.